Biomarkers of cardiovascular damage

Medical Principles and Practice

Volumn 16, Issue 4, 2007, Pages 247-261

  Collinson, Paul O ^a,b   Gaze, David C ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Acute coronary syndrome; Biomarkers; Cardiac troponin I; Cardiac troponin T; Chest pain; Ischaemia; Ischaemia modified albumin; Myocardial infarction; N terminal B type natriuretic peptide; Prognostic risk assessment

Indexed keywords

ALBUMIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CARVEDILOL; CHOLINE; FATTY ACID; PLACEBO; TROPONIN I; TROPONIN T; VALSARTAN;

ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE; ANGIOCARDIOGRAPHY; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DISEASE ASSOCIATION; ELECTROCARDIOGRAM; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; PREDICTION; PROGNOSIS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; ST SEGMENT ELEVATION; THORAX PAIN; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLINE; ELECTROCARDIOGRAPHY; FATTY ACIDS, NONESTERIFIED; HUMANS; KIDNEY FAILURE; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; SERUM ALBUMIN; SYNDROME; TROPONIN I; TROPONIN T;

EID: 34249778974     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000102146     Document Type: Review

References (130)

1. Davies MJ: Stability and instability: two faces of coronary atherosclerosis - The Paul Dudley White Lecture 1995. Circulation 1996;94:2013-2020.
2. Rioufol G, Finet G, Ginon I, Andre-Fouet X, Rossi R, Vialle E, Desjoyaux E, Convert G, Huret JF, Tabib A: Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation 2002;106:804-808.
3. Hong MK, Mintz GS, Lee CW, Kim YH, Lee SW, Song JM, Han KH, Kang DH, Song JK, Kim JJ, Park SW, Park SJ: Comparison of coronary plaque rupture between stable angina and acute myocardial infarction: a three-vessel intravascular ultrasound study in 235 patients. Circulation 2004;110:928-933.
4. Davies MJ, Thomas AC, Knapman PA, Hangartner JR: Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986;73:418-427.
5. Falk E: Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985;71:699-708.
6. Apple FS, Wu AH, Mair J, Ravkilde J, Panteghini M, Tate J, Pagani F, Christenson RH, Mockel M, Danne O, Jaffe AS: Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005;51:810-824.
7. Shaikh NA, Downar E: Time course of changes in porcine myocardial phospholipid levels during ischemia: a reassessment of the lysolipid hypothesis. Circ Res 1981;49:316-325.
8. Deves R, Reyes G, Krupka RM: The carrier reorientation step in erythrocyte choline transport: pH effects and the involvement of a carrier ionizing group. J Membr Biol 1986;93:165-175.
9. Danne O, Mockel M, Lueders C, Mugge C, Zschunke GA, Luft H, Muller C, Frei U: Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. Am J Cardiol 2003;91:1060-1067.
10. Kurien VA, Oliver MF: Serum-free-fatty-acids after acute myocardial infarction and cerebral vascular occlusion. Lancet 1966;2:122-127.
11. Kleinfeld AM, Prothro D, Brown DL, Davis RC, Richieri GV, DeMaria A: Increases in serum unbound free fatty acid levels following coronary angioplasty. Am J Cardiol 1996;78:1350-1354.
12. Aguirre FV, Younis LT, Chaitman BR, Ross AM, McMahon RP, Kern MJ, Berger PB, Sopko G, Rogers WJ, Shaw L , Knatterud G , Braunwald E: Early and 1-year clinical outcome of patients' evolving non-Q-wave versus Q-wave myocardial infarction after thrombolysis: results from The TIMI II Study. Circulation 1995;91:2541-2548.
13. Chevion M, Jiang Y, Har-El R, Berenshtein E, Uretzky G, Kitrossky N: Copper and iron are mobilized following myocardial ischemia: possible predictive criteria for tissue injury. Proc Natl Acad Sci USA 1993;90:1102-1106.
14. Cobbe SM, Poole-Wilson PA: The time of onset and severity of acidosis in myocardial ischaemia. J Mol Cell Cardiol 1980;12:745-760.
15. McCord JM: Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985;312:159-163.
16. Sadler PJ, Tucker A, Viles JH: Involvement of a lysine residue in the N-terminal Ni2+ and Cu2+ binding site of serum albumins: comparison with Co2+, Cd2+ and Al3+. Eur J Biochem 1994;220:193-200.
17. Chan B, Dodsworth N, Woodrow J, Tucker A, Harris R: Site-specific N-terminal auto-degradation of human serum albumin. Eur J Biochem 1995;227:524-528.
18. Bar-Or D, Lau E, Winkler JV: A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia: a preliminary report. J Emerg Med 2000;19:311-315.
19. Bar-Or D, Winkler JV, Vanbenthuysen K, Harris L, Lau E, Hetzel FW: Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: a preliminary comparison to creatine kinase-MB, myoglobin, and troponin I. Am Heart J 2001;141:985-991.
20. Bar-Or D, Curtis G, Rao N, Bampos N, Lau E: Characterization of the Co2+ and Ni2+ binding amino-acid residues of the N-terminus of human albumin: an insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem 2001;268:42-47.
21. Bhagavan NV, Lai EM, Rios PA, Yang J, Ortega-Lopez AM, Shinoda H, Honda SA, Rios CN, Sugiyama CE, Ha CE: Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem 2003;49:581-585.
22. Wu AH, Morris DL, Fletcher DR, Apple FS, Christenson RH, Painter PC: Analysis of the Albumin Cobalt Binding (ACB) test as an adjunct to cardiac troponin I for the early detection of acute myocardial infarction. Cardiovasc Toxicol 2001;1:147-151.
23. Christenson RH, Duh SH, Sanhai WR, Wu AH, Holtman V, Painter P, Branham E, Apple FS, Murakami M, Morris DL: Characteristics of an Albumin Cobalt Binding Test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem 2001;47:464-470.
24. Sinha MK, Gaze DC, Tippins JR, Collinson PO, Kaski JC: Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation 2003;107:2403-2405.
25. Garrido IP, Roy D, Calvino R, Vazquez-Rodriguez JM, Aldama G, Cosin-Sales J, Quiles J, Gaze DC, Kaski JC: Comparison of ischemia-modified albumin levels in patients undergoing percutaneous coronary intervention for unstable angina pectoris with versus without coronary collaterals. Am J Cardiol 2004;93:88-90.
26. Quiles J, Roy D, Gaze D, Garrido IP, Avanzas P, Sinha M, Kaski JC: Relation of ischemia-modified albumin (IMA) levels following elective angioplasty for stable angina pectoris to duration of balloon-induced myocardial ischemia. Am J Cardiol 2003;92:322-324.
27. Roy D, Quiles J, Sinha M, Aldama G, Gaze D, Kaski JC: Effect of direct-current cardioversion on ischemia-modified albumin levels in patients with atrial fibrillation. Am J Cardiol 2004;93:366-368.
28. Sinha MK, Roy D, Gaze DC, Collinson PO, Kaski JC: Role of 'ischemia modified albumin', a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg Med J 2004;21:29-34.
29. Collinson PO, Gaze DC, Bainbridge K, Morris F, Morris B, Price A, Goodacre S: Utility of admission cardiac troponin and 'Ischemia Modified Albumin' measurements for rapid evaluation and rule out of suspected acute myocardial infarction in the emergency department. Emerg Med J 2006;23:256-261.
30. Peacock F, Morris DL, Anwaruddin S, Christenson RH, Collinson PO, Goodacre SW, Januzzi JL, Jesse RL, Kaski JC, Kontos MC, Lefevre G, Mutrie D, Sinha MK, Uettwiller-Geiger D, Pollack CV: Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. Am Heart J 2006;152:253-262.
31. Gaze DC, Crompton L, Collinson P: Ischemia-modified albumin concentrations should be interpreted with caution in patients with low serum albumin concentrations. Med Princ Pract 2006;15:322-324.
32. Zapico-Muniz E, Santalo-Bel M, Merce-Muntanola J, Montiel JA, Martinez-Rubio A, Ordonez-Llanos J: Ischemia-modified albumin during skeletal muscle ischemia. Clin Chem 2004;50:1063-1065.
33. Wu AH, Valdes R Jr, Apple FS, Gornet T, Stone MA, Mayfield-Stokes S, Ingersoll-Stroubos AM, Wiler B: Cardiac troponin-T immunoassay for diagnosis of acute myocardial infarction. Clin Chem 1994;40:900-907.
34. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000;21:1502-1513.
35. Wu AH, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes R Jr: National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem 1999;45:1104-1121.
36. Collinson PO, Stubbs PJ, Kessler AC: Multicentre evaluation of the diagnostic value of cardiac troponin T, CK-MB mass, and myoglobin for assessing patients with suspected acute coronary syndromes in routine clinical practice. Heart 2003;89:280-286.
37. Collinson PO, Chandler HA, Stubbs PJ, Moseley DS, Lewis D, Simmons MD: Measurement of serum troponin T, creatine kinase MB isoenzyme, and total creatine kinase following arduous physical training. Ann Clin Biochem 1995;32:450-453.
38. Bodor GS, Survant L, Voss EM, Smith S, Porterfield D, Apple FS: Cardiac troponin T composition in normal and regenerating human skeletal muscle. Clin Chem 1997;43:476-484.
39. Ricchiuti V, Voss EM, Ney A, Odland M, Anderson PA, Apple FS: Cardiac troponin T isoforms expressed in renal diseased skeletal muscle will not cause false-positive results by the second generation cardiac troponin T assay by Boehringer Mannheim. Clin Chem 1998;44:1919-1924.
40. Apple FS, Ricchiuti V, Voss EM, Anderson PA, Ney A, Odland M: Expression of cardiac troponin T isoforms in skeletal muscle of renal disease patients will not cause false-positive serum results by the second generation cardiac troponin T assay. Eur Heart J 1998;19(suppl N):N30-N33.
41. Davis GK, Labugger R, Van Eyk JE, Apple FS: Cardiac troponin T is not detected in Western blots of diseased renal tissue. Clin Chem 2001;47:782-783.
42. Haller C, Zehelein J, Remppis A, Muller-Bardorff M, Katus HA: Cardiac troponin T in patients with end-stage renal disease: absence of expression in truncal skeletal muscle. Clin Chem 1998;44:930-938.
43. Fredericks S, Murray JF, Bewick M, Chang R, Collinson PO, Carter ND, Holt DW: Cardiac troponin T and creatine kinase MB are not increased in exterior oblique muscle of patients with renal failure. Clin Chem 2001;47:1023-1030.
44. Fredericks S, Bainbridge K, Fenske CD, Gaze D, Collinson PO, Carter ND, Holt DW: Cardiac troponin-I content of skeletal muscle in patients with renal failure. Clin Biochem 2002;35:421-423.
45. Fredericks S, Bainbridge K, Murray JF, Collinson PO, Carter ND, Holt DW: Measurement of cardiac troponin I in striated muscle using three experimental methods. Ann Clin Biochem 2003;40:244-248.
46. Collinson PO, Boa FG, Gaze DC: Measurement of cardiac troponins. Ann Clin Biochem 2001;38:423-449.
47. Hamm CW, Ravkilde J, Gerhardt W, Jorgensen P, Peheim E, Ljungdahl L, Goldmann B, Katus HA: The prognostic value of serum troponin T in unstable angina. N Engl J Med 1992;327:146-150.
48. Stubbs P, Collinson P, Moseley D, Greenwood T, Noble M: Prospective study of the role of cardiac troponin T in patients admitted with unstable angina. BMJ 1996;313:262-264.
49. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E: Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335:1342-1349.
50. Galvani M, Ottani F, Ferrini D, Ladenson JH, Destro A, Baccos D, Rusticali F, Jaffe AS: Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina. Circulation 1997;95:2053-2059.
51. Luscher MS, Thygesen K, Ravkilde J, Heickendorff L: Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease. TRIM Study Group. Thrombin Inhibition in Myocardial Ischemia. Circulation 1997;96:2578-2585.
52. Collinson PO, Wiggins N, Gaze DC: Clinical evaluation of the ACS:180 cardiac troponin I assay. Ann Clin Biochem 2001;38:509-519.
53. Olatidoye AG, Wu AH, Feng YJ, Waters D: Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta-analysis comparing published studies. Am J Cardiol 1998;81:1405-1410.
54. Ottani F, Galvani M, Nicolini FA, Ferrini D, Pozzati A, Di Pasquale G , Jaffe AS: Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J 2000;140:917-927.
55. Heidenreich PA, Alloggiamento T, Melsop K, McDonald KM, Go AS, Hlatky MA: The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol 2001;38:478-485.
56. Labugger R, Organ L, Collier C, Atar D, Van Eyk JE: Extensive troponin I and T modification detected in serum from patients with acute myocardial infarction. Circulation 2000;102:1221-1226.
57. McDonough JL, Labugger R, Pickett W, Tse MY, MacKenzie S, Pang SC, Atar D, Ropchan G, Van Eyk JE : Cardiac troponin I is modified in the myocardium of bypass patients. Circulation 2001;103:58-64.
58. Stubbs P, Collinson P, Moseley D, Greenwood T, Noble M: Prognostic significance of admission troponin T concentrations in patients with myocardial infarction. Circulation 1996;94:1291-1297.
59. Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, O'Hanesian MA, Wagner GS, Kleiman NS, Harrell FE Jr, Califf RM, Topol EJ; GUSTO IIA Investigators: Cardiac troponin T levels for risk stratification in acute myocardial ischemia. N Engl J Med 1996;335:1333-1341.
60. Topol EJ, Bates ER, Walton JA Jr, Baumann G, Wolfe S, Maino J, Bayer L, Gorman L, Kline EM, O'Neill WW: Community hospital administration of intravenous tissue plasminogen activator in acute myocardial infarction: improved timing, thrombolytic efficacy and ventricular function. J Am Coll Cardiol 1987;10:1173-1177.
61. Licka M, Zimmermann R, Zehelein J, Deng ler TJ, Katus HA, Kubler W: Troponin T concentrations 72 hours after myocardial infarction as a serological estimate of infarct size. Heart 2002;87:520-524.
62. Remppis A, Ehlermann P, Giannitsis E, Greten T, Most P, Muller-Bardorff M, Katus HA: Cardiac troponin T levels at 96 hours reflect myocardial infarct size: a pathoanatomical study. Cardiology 2000;93:249-253.
63. Rao AC, Collinson PO, Canepa-Anson R, Joseph SP: Troponin T measurement after myocardial infarction can identify left ventricular ejection of less than 40%. Heart 1998;80:223-225.
64. Rao AC, Collinson PO, Rose AJ, John C, Canepa-Anson R, Joseph SP: Prospective evaluation of the role of routine cardiac troponin T measurement to identify left ventricular ejection fraction <40% after first myocardial infarction. Heart 2003;89:559-560.
65. Panteghini M, Cuccia C, Bonetti G, Giubbini R, Pagani F, Bonini E: Single-point cardiac troponin T at coronary care unit discharge after myocardial infarction correlates with infarct size and ejection fraction. Clin Chem 2002;48:1432-1436.
66. Panteghini M, Bonetti G, Pagani F, Stefini F, Giubbini R, Cuccia C: Measurement of troponin I 48 h after admission as a tool to rule out impaired left ventricular function in patients with a first myocardial infarction. Clin Chem Lab Med 2005;43:848-854.
67. Steen H, Giannitsis E, Futterer S, Merten C, Juenger C, Katus HA: Cardiac troponin T at 96 hours after acute myocardial infarction correlates with infarct size and cardiac function. J Am Coll Cardiol 2006;48:2192-2194.
68. Lindahl B, Andren B, Ohlsson J, Venge P, Wallentin L;FRISC Study Group: Noninvasive risk stratification in unstable coronary artery disease: exercise test and biochemical markers. Am J Cardiol 1997;80:40E-44E.
69. Kontos MC: Evaluation of the Emergency Department chest pain patient. Cardiol Rev 2001;9:266-275.
70. Kontos MC, Jesse RL: Evaluation of the emergency department chest pain patient. Am J Cardiol 2000;85:32B-39B.
71. James S, Armstrong P, Califf R, Simoons ML, Venge P, Wallentin L, Lindahl B: Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial. Am J Med 2003;115:178-184.
72. Lindahl B, Venge P, Wallentin L;Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group: Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. J Am Coll Cardiol 1997;29:43-48.
73. Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van de Werf F, de Torbal A, Armstrong PW, Wallentin LC, Wilcox RG, Simes J, Califf RM, Topol EJ, Simoons ML: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-198.
74. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E; TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy) - Thrombolysis in Mycardial Infarction 18 Investigators: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-1887.
75. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, De Feyter PJ, Specchia G, Ruzyllo W; Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology: Management of acute coronary syndromes in patients presenting without persistent STsegment elevation. Eur Heart J 2000;21:1406-1432.
76. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, De Feyter PJ, Specchia G, Ruzyllo W: Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002;23:1809-1840.
77. Goodacre S, Nicholl J, Dixon S, Cross E, Angelini K, Arnold J, Revill S, Locker T, Capewell SJ, Quinney D, Campbell S, Morris F: Randomised controlled trial and economic evaluation of a chest pain observation unit compared with routine care. BMJ 2004;328:254-260.
78. Goodacre SW, Morris FM, Campbell S, Arnold J, Angelini K: A prospective, observational study of a chest pain observation unit in a British hospital. Emerg Med J 2002;19:117-121.
79. McCord J, Nowak RM, McCullough PA, Foreback C, Borzak S, Tokarski G, Tomlanovich MC, Jacobsen G, Weaver WD: Ninetyminute exclusion of acute myocardial infarction by use of quantitative point-of-care testing of myoglobin and troponin I. Circulation 2001;104:1483-1488.
80. Collinson PO, Gaze DC, Morris F, Morris B, Price A, Goodacre S: Comparison of biomarker strategies for rapid rule out of myocardial infarction in the emergency department using ACC/ESC diagnostic criteria. Ann Clin Biochem 2006;43:273-280.
81. Bhayana V, Gougoulias T, Cohoe S, Henderson AR: Discordance between results for serum troponin T and troponin I in renal disease. Clin Chem 1995;41:312-317.
82. Collinson PO, Hadcocks L, Foo Y, Rosalki SB, Stubbs PJ, Morgan SH, O'Donnell J: Cardiac troponins in patients with renal dysfunction. Ann Clin Biochem 1998;35:380-386.
83. Apple FS, Murakami MM, Pearce LA, Herzog CA: Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 2002;106:2941-2945.
84. Khan NA, Hemmelgarn BR, Tonelli M, Thompson CR, Levin A: Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a metaanalysis. Circulation 2005;112:3088-3096.
85. Sharma R, Gaze DC, Pellerin D, Mehta RL, Gregson H, Streather CP, Collinson PO, Brecker SJ: Cardiac structural and functional abnormalities in end stage renal disease patients with elevated cardiac troponin T. Heart 2006;92:804-809.
86. Akkerhuis KM, Alexander JH, Tardiff BE, Boersma E, Harrington RA, Lincoff AM, Simoons ML: Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different? Circulation 2002;105:554-556.
87. Herrmann J: Peri-procedural myocardial injury: 2005 update. Eur Heart J 2005;26:2493-2519.
88. Ricciardi MJ, Wu E, Davidson CJ, Choi KM, Klocke FJ, Bonow RO, Judd RM, Kim RJ: Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 2001;103:2780-2783.
89. Selvanayagam JB, Porto I, Channon K, Petersen SE, Francis JM, Neubauer S, Banning AP: Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation 2005;111:1027-1032.
90. Bhatt DL, Topol EJ: Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Periprocedural cardiac enzyme elevation predicts adverse outcomes. Circulation 2005;112:906-915.
91. Cutlip DE, Kuntz RE: Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Cardiac enzyme elevation after successful percutaneous coronary intervention is not an independent predictor of adverse outcomes. Circulation 2005;112:916-922.
92. Ioannidis JP, Karvouni E, Katritsis DG: Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol 2003;42:1406-1411.
93. Cavallini C, Savonitto S, Violini R, Arraiz G, Plebani M, Olivari Z, Rubartelli P, Battaglia S, Niccoli L, Steffenino G, Ardissino D: Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur Heart J 2005;26:1494-1498.
94. Miller WL, Garratt KN, Burritt MF, Lennon RJ, Reeder GS, Jaffe AS: Baseline troponin level: key to understanding the importance of post-PCI troponin elevations. Eur Heart J 2006;27:1061-1069.
95. McLaurin M, Apple FS, Henry TD, Sharkey SW: Cardiac troponin I and T concentrations in patients with cocaine-associated chest pain. Ann Clin Biochem 1996;33:183-186.
96. Kontos MC, Anderson FP, Ornato JP, Tatum JL, Jesse RL: Utility of troponin I in patients with cocaine-associated chest pain. Acad Emerg Med 2002;9:1007-1013.
97. Kontos MC, Jesse RL, Tatum JL, Ornato JP: Coronary angiographic findings in patients with cocaine-associated chest pain. J Emerg Med 2003;24:9-13.
98. Gaze DC, Collinson PO: Cardiac troponins as biomarkers of drug- and toxin-induced cardiac toxicity and cardioprotection. Expert Opin Drug Metab Toxicol 2005;1:715-725.
99. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE: The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004;351:145-153.
100. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM: Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474-2481.
101. Collinson PO, Stubbs PJ: Are troponins confusing? Heart 2003;89:1285-1287.
102. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA: Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997;47:287-296.
103. Collinson PO, Barnes SC, Gaze DC, Galasko G, Lahiri A, Senior R: Analytical performance of the N-terminal pro-B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail 2004;6:365-368.
104. Barnes SC, Collinson PO, Galasko G, Lahiri A, Senior R: Evaluation of N-terminal pro-B type natriuretic peptide analysis on the Elecsys 1010 and 2010 analysers. Ann Clin Biochem 2004;41:459-563.
105. Sokoll LJ, Baum H, Collinson PO, Gurr E, Haass M, Luthe H, Morton JJ, Nowatzke W, Zingler C: Multicenter analytical performance evaluation of the Elecsys proBNP assay. Clin Chem Lab Med 2004;42:965-972.
106. Wu AH, Packer M, Smith A, Bijou R, Fink D, Mair J, Wallentin L, Johnston N, Feldcamp CS, Haverstick DM, Ahnadi CE, Grant A, Despres N, Bluestein B, Ghani F: Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. Clin Chem 2004;50:867-873.
107. Apple FS, Panteghini M, Ravkilde J, Mair J, Wu AH, Tate J, Pagani F, Christenson RH, Jaffe AS; Committee on Standardization of Markers of Cardiac Damage of the IFCC: Quality specifications for B-type natriuretic peptide assays. Clin Chem 2005;51:486-493.
108. Remme WJ, Swedberg K: Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-1560.
109. Cowie MR, Zaphiriou A: Management of chronic heart failure. BMJ 2002;325:422-425.
110. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, Tunstall-Pedoe H, McMurray JJ, Dargie H: Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
111. McDonagh TA, Morrison CE, Lawrence A, Ford I, Tunstall-Pedoe H, McMurray JJ, Dargie HJ: Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997;350:829-833.
112. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Sutton GC: Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1349-1353.
113. Zaphiriou A, Robb S, Murray-Thomas T, Mendez G, Fox K, McDonagh T, Hardman SM, Dargie HJ, Cowie MR: The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail 2005;7:537-541.
114. Hobbs FD, Davis RC, Roalfe AK, Hare R, Davies MK, Kenkre JE: Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ 2002;324:1498-1503.
115. Hobbs FD, Davis RC, Roalfe AK, Hare R, Davies MK: Reliability of N-terminal proBNP assay in diagnosis of left ventricular systolic dysfunction within representative and high risk populations. Heart 2004;90:866-870.
116. Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F: Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma Nterminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 2004;90:297-303.
117. Galasko GI, Lahiri A, Barnes SC, Collinson P, Senior R: What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? Eur Heart J 2005;26:2269-2276.
118. Richards AM, Doughty R, Nicholls MG, Macmahon S, Ikram H, Sharpe N, Espiner EA, Frampton C, Yandle TG; Australia-New Zealand Heart Failure Group: Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation 1999;99:786-792.
119. Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang YT, Bevilacqua M, Salio M, Cardano P, Dunselman PH, Holwerda NJ, Tognoni G, Cohn JN; Valsartan Heart Failure Trial Investigators: Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002;106:2454-2458.
120. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN; Val-HeFT Investigators: Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278-1283.
121. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-1130.
122. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA; Breathing Not Properly Multinational Study Investigators: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-167.
123. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards, M: NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients - The International Collaborative of NT-proBNP Study. Eur Heart J 2006;27:330-337.
124. Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB: The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95:948-954.
125. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, Pfisterer M, Perruchoud AP: Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350:647-654.
126. De Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald W: The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-1021.
127. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald E: Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002;105:1760-1763.
128. Jernberg T, Stridsberg M, Venge P, Lindahl B: N-terminal pro-brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation PG. J Am Coll Cardiol 2002;40:437-445.
129. Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, Frampton C, Turner J, Crozier IG, Yandle TG: B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003;107:2786-2792.
130. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, Barnathan ES, Califf R, Topol EJ, Simoons ML, Wallentin L: N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003;108:275-281.